Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Soligenix Inc Common (SNGX)  
$0.40 0.00 (0.00%) as of 4:30 Thu 2/9


Download
   
Exchange: OTC Bulletin Board
Security Type: Common
Shares Out: 40,080,000
Market Cap: 16.04(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.4002 - $0.4002
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases. Co.'s business segments are: Specialized BioTherapeutics, which is developing and moving toward potential commercialization of HyBryte™, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma; and Public Health Solutions, which includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and other infectious disease and its vaccine programs targeting filoviruses and CiVax™, its vaccine candidate for the prevention of COVID-19.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 39
  Page 2 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Brughera Marco Maria Director   –       •      –    2016-12-16 4 B $3.16 $6,320 D/D 2,000 2,750 2.39     -
   Krumeich Karen R SVP and CFOOfficer   •       –      –    2016-06-16 3 IO $0.00 $0 D/D 0 13,000     -
   Zeldis Jerome B Director   –       •      –    2015-12-23 4 B $1.27 $3,175 D/D 2,500 69,166 2.31     -
   Schaber Christopher Chairman, CEO and President   •       •      –    2015-12-22 4 B $1.29 $12,878 D/D 10,000 85,761 2.81     -
   Lapointe Gregg Anthony Director   –       •      –    2015-08-31 4 OE $0.30 $7,500 D/D 25,000 73,781     -
   Schaber Christopher Chairman, CEO and President   •       •      –    2015-07-01 4 OE $0.61 $4,357 D/D 7,143 82,904     -
   Zeldis Jerome B Director   –       •      –    2015-04-09 4 OE $0.61 $10,893 D/D 17,857 66,666     -
   Brownlie Keith L Director   –       •      –    2015-04-09 4 OE $0.61 $8,714 D/D 14,286 50,000     -
   Schaber Christopher Chairman, CEO and President   •       •      –    2014-12-22 4 B $1.21 $10,001 D/D 8,265 75,761 2.81     -
   Warusz Joseph Michael VP of Finance/Acting CFO   •       –      –    2014-12-22 4 B $1.21 $10,001 D/D 8,265 12,955 2.74     -
   Brughera Marco Maria Director   –       •      –    2014-08-05 4 OE $2.01 $15,075 D/D 7,500 7,500     -
   Warusz Joseph Michael VP of Admin, Controller / PAO   •       –      –    2014-05-19 4 OE $0.64 $3,002 D/D 4,690 4,690     -
   Brownlie Keith L Director   –       •      –    2014-05-14 4 OE $0.30 $5,000 D/D 16,667 35,714     -
   Schaber Christopher Chairman, CEO and President   •       •      –    2014-05-13 4 OE $0.64 $5,002 D/D 7,815 67,496     -

  39 Records found
  1  2    
  Page 2 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed